Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Failure 1Hepatitis C 1Hepatitis B 1Hepatic Insufficiency 1HIV Infections 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 300Fluorouracil 272Bevacizumab 237Gemcitabine 236Leucovorin 212Capecitabine 207pembrolizumab 201Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 107Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Raltegravir Potassium × Gastrointestinal × 1 year × Clear all
NCT01022476 2026-04-06

LIVERAL

ANRS, Emerging Infectious Diseases

Phase 1/2 Completed
14 enrolled
Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, HIV Infections, Liver Failure, Hepatic Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡